Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06268847
Other study ID # DERMATIDYSS
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 9, 2024
Est. completion date June 18, 2024

Study information

Verified date February 2024
Source Abyss Ingredients
Contact Elodie BOUVRET, MD
Phone +33777849366
Email elodie@abyss-ingredients.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This interventional, double-blind, randomized, placebo-controlled study aims to evaluate the effect of a marine by-product hydrolysate supplementation on the reduction of atopic dermatitis symptoms.


Description:

The study will be carried out with 108 subjects divided in 3 groups of 36 subjects who will be supplemented with two dosages of the food supplement or a placebo. This study intends to assess objectively and subjectively the efficacy of a food supplement claimed to improve the skin condition related to atopic dermatitis. The objectives of the study consist in the evaluation of the supplementation to imrove the skin condition and symptoms on atopic dermatitis (by SCORAD), to reduce the eczema and severity on atopic dermatitis (by SORAD and Eczema Area and Severity Index), to reduce the inflammatory signs (by Investigator Global Assessment scale), to moisturize and to improve/maintin the skin barrier.


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date June 18, 2024
Est. primary completion date June 18, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Phototype: I to V; - Subjects with atopic skin (with at least 1 visible xerosis + inflammation on the body); - Subjects with a history background of asthma, rhinitis and/or allergic conjunctivitis; - Subjects with SCORAD between 8 and 30 (at least 50% or more having around 8-10); - Subjects with BMI between 20 and 30 kg/m2 (limits included); - Subjects who have not recently participated in another similar study; - Willingness to take supplements for the duration of the study; - Willingness not to use products likely to interfere with the test product (collagen, hyaluronic acid, anti-stress products); - Willingness not to change lifestyle habits; - Willingness to avoid intensive UV exposure; - Use of contraception that should not be modified during the study. - Healthy subject; - Mentally healthy subject according to Investigator's opinion; - Subject having given his/her free informed, written consent; - Subject agrees to taking photograph and then use the image after its pseudonymization; - Subject willing to adhere to the protocol and study procedures; - Subject able to understand the study; - Subject available to attend the study visits. Exclusion Criteria: - Pregnant or nursing woman or woman planning to get pregnant during the study; - Cutaneous marks on the experimental areas, which could interfere with the assessment of skin reactions; - Subjects who have participated in the last 3 months or are currently participating in another clinical trial that may interfere with the evaluation of the primary endpoint (endpoint AD); - Current administration of antibiotics; - Known history of chronic disease such as congenital heart disease, liver or kidney disease, or immune deficiency; - Topical treatment with immunomodulators (tacrolimus or pimecrolimus) in the three months prior to registration; - Application of moisturizing products on the experimental area the day of the inclusion of the study; - Acute or chronic infectious diseases; - Not meet inclusion criteria; - Those undergoing aesthetic medicine (fillers, hyaluronic acid injections, botox) that could interference in the experimental area; - Subjects suffering Alimentary/Eating disorders (i.e. bulimia, psychogenic eating disorders, etc.) - Subjects having frequent stomach burn; - Allergy or intolerance to any ingredient of the experimental food supplement; - Subjects with diabetes mellitus; - Fish and/or iodine allergy; - Intestinal conditions or disorders (Crohn's disease, colitis, irritable bowel syndrome, intestinal malabsorption...) - Recent change, forecast of initiation of an hormonal treatment or change of the usual hormonal treatment during the study or 3 months before the starting of the study; - Subject having undergone a surgery under general anesthesia within the previous month; - Exposure in UVA ray sunbed during the 3 months before the start of the study on the experimental area or during the study; - Subjects protected by the law; - Subject employed by EUROFINS PRODUCT TESTING, COSMETICS & PERSONAL CARE SPAIN, S.L.U.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo
The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product. 2 capsules per day for 90 days of placebo.
ACT01
2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
ACT02
2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.

Locations

Country Name City State
Spain Eurofins Barcelona

Sponsors (2)

Lead Sponsor Collaborator
Abyss Ingredients Eurofins

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary SCORAD (SCORing Atopic Dermatitis) 12 weeks
Secondary EASI (Eczema Area and Severity Index) 12 weeks
Secondary Investigator Global Assessment scale To evaluate the inflammatory signs. 12 weeks
Secondary Corneometer To measure skin hydration. 12 weeks
Secondary Tewameter To evaluate the epidermal barrier integrity through the transepidermal water loss. 12 weeks
Secondary Quality of Life Index - Perceived Stress Auto-questionnaire 12 weeks
Secondary Participant's Satisfaction Auto-questionnaire 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2